Effects of stimulation of dopamine D1 receptors on the cortical EEG in rats: different influences by a blockade of D2 receptors and by an activation of putative dopamine autoreceptors

Striatal neurons expressing dopamine D1 receptor promote wakefulness in mice

Patients with Parkinson's disease (PD) suffer from severe sleep disorders. Pathophysiology of the basal ganglia (BG) underlies PD, and the dorsal striatum represents the major input pathway of the BG. However, the roles and mechanisms of the dorsal striatum in controlling sleep-wake cycles remain unknown. To demonstrate the contribution of dopamine D₁ receptor (D₁R)-positive neurons within the dorsal striatum in promoting wakefulness, we combined optogenetic manipulations and fiber photometry with electroencephalography/electromyography recording in D₁R-Cre mice. As a result, optogenetic activation of striatal D₁R neurons induced immediate transitions from non-rapid eye movement (NREM) sleep to wakefulness, whereas inhibition of striatal D₁R neurons attenuated wakefulness by chemogenetics. Multi-channel fiber photometry recordings revealed that the activity of striatal D₁R neurons synchronized with that of BG upstreams, namely the prefrontal cortex and mediodorsal thalamus, in terms of immediate increase in activity during NREM-to-wake transitions and rapid decease during wake-to-NREM transitions. Further optogenetic manipulations revealed a prominent contribution of striatal D₁R neurons in control of wakefulness by upstream, corticostriatal, thalamostriatal, and nigrostriatal projections and via downstream, striato-entopeduncular, or striatonigral pathways. Taken together, our findings revealed a circuit regulating wakefulness through striatal D₁R neurons. Striatal D₁R neurons play an important role in controlling wakefulness by integrating the corticostriatal, thalamostriatal, and nigrostriatal projections and innervation of striato-entopeduncular or striatonigral pathways.

Pleasure: The missing link in the regulation of sleep

Although largely unrecognized by sleep scholars, sleeping is a pleasure. This report aims first, to fill the gap: sleep, like food, water and sex, is a primary reinforcer. The levels of extracellular mesolimbic dopamine show circadian oscillations and mark the "wanting" for pro-homeostatic stimuli. Further, the dopamine levels decrease during waking and are replenished during sleep, in opposition to sleep propensity. The wanting of sleep, therefore, may explain the homeostatic and circadian regulation of sleep. Accordingly, sleep onset occurs when the displeasure of excessive waking is maximal, coinciding with the minimal levels of mesolimbic dopamine. Reciprocally, sleep ends after having replenished the limbic dopamine levels. Given the direct relation between waking and mesolimbic dopamine, sleep must serve primarily to gain an efficient waking. Pleasant sleep (i.e. emotional sleep), can only exist in animals capable of feeling emotions. Therefore, although sleep-like states have been described in invertebrates and primitive vertebrates, the association sleep-pleasure clearly marks a difference between the sleep of homeothermic vertebrates and cool blooded animals.

The effects of dexamphetamine on the resting-state electroencephalogram and functional connectivity

The catecholamines-dopamine and noradrenaline-play important roles in directing and guiding behavior. Disorders of these systems, particularly within the dopamine system, are associated with several severe and chronically disabling psychiatric and neurological disorders. We used the recently published group independent components analysis (ICA) procedure outlined by Chen et al. (2013) to present the first pharmaco-EEG ICA analysis of the resting-state EEG in healthy participants administered 0.45 mg/kg dexamphetamine. Twenty-eight healthy participants between 18 and 41 were recruited. Bayesian nested-domain models that explicitly account for spatial and functional relationships were used to contrast placebo and dexamphetamine on component spectral power and several connectivity metrics. Dexamphetamine led to reductions across delta, theta, and alpha spectral power bands that were predominantly localized to Frontal and Central regions. Beta 1 and beta 2 power were reduced by dexamphetamine at Frontal ICs, while beta 2 and gamma power was enhanced by dexamphetamine in posterior regions, including the parietal, occipital-temporal, and occipital regions. Power-power coupling under dexamphetamine was similar for both states, resembling the eyes open condition under placebo. However, orthogonalized measures of power coupling and phase coupling did not show the same effect of dexamphetamine as power-power coupling. We discuss the alterations of low- and high-frequency EEG power in response to dexamphetamine within the context of disorders of dopamine regulation, in particular schizophrenia, as well as in the context of a recently hypothesized association between low-frequency power and aspects of anhedonia. Hum Brain Mapp 37:570-588, 2016. © 2015 Wiley Periodicals, Inc.

Roles of adrenergic α1 and dopamine D1 and D2 receptors in the mediation of the desynchronization effects of modafinil in a mouse EEG synchronization model

BACKGROUND

Synchronized electroencephalogram (EEG) activity is observed in pathological stages of cognitive impairment and epilepsy. Modafinil, known to increase the release of catecholamines, is a potent wake-promoting agent, and has shown some abilities to desynchronize EEG,but its receptor mechanisms by which modafinil induces desynchoronization remain to be elucidated. Here we used a pharmacological EEG synchronization model to investigate the involvement of adrenergic α1 receptors (R, α1R) and dopamine (DA) D1 and D2 receptors (D1Rs and D2Rs) on modafinil-induced desynchronization in mice.

METHODOLOGY/PRINCIPAL FINDINGS

Mice were treated with cholinergic receptor antagonist scopolamine and monoamine depletor reserpine to produce experimental EEG synchronization characterized by continuous large-amplitude synchronized activity, with prominent increased delta and decreased theta, alpha, and beta power density. The results showed that modafinil produced an EEG desynchronization in the model. This was characterized by a general decrease in amplitude of all the frequency bands between 0 and 20 Hz, a prominent reduction in delta power density, and an increase in theta power density. Adrenergic α1R antagonist terazosin (1 mg/kg, i.p.) completely antagonized the EEG desynchronization effects of modafinil at 90 mg/kg. However, DA D1R and D2R blockers partially attenuated the effects of modafinil. The modafinil-induced decrease in the amplitudes of the delta, theta, alpha, and beta waves and in delta power density were completely abolished by pretreatment with a combination of the D1R antagonist SCH 23390 (30 µg/kg) and the D2R antagonist raclopride (2 mg/kg, i.p.).

CONCLUSIONS/SIGNIFICANCE

These results suggest that modafinil-mediated desynchronization may be attributed to the activation of adrenergic α1R, and dopaminergic D1R and D2R in a model of EEG synchronization.

EEG delta oscillations as a correlate of basic homeostatic and motivational processes

Functional significance of delta oscillations is not fully understood. One way to approach this question would be from an evolutionary perspective. Delta oscillations dominate the EEG of waking reptiles. In humans, they are prominent only in early developmental stages and during slow-wave sleep. Increase of delta power has been documented in a wide array of developmental disorders and pathological conditions. Considerable evidence on the association between delta waves and autonomic and metabolic processes hints that they may be involved in integration of cerebral activity with homeostatic processes. Much evidence suggests the involvement of delta oscillations in motivation. They increase during hunger, sexual arousal, and in substance users. They also increase during panic attacks and sustained pain. In cognitive domain, they are implicated in attention, salience detection, and subliminal perception. This evidence shows that delta oscillations are associated with evolutionary old basic processes, which in waking adults are overshadowed by more advanced processes associated with higher frequency oscillations. The former processes rise in activity, however, when the latter are dysfunctional.

Role of dopamine receptors on electroencephalographic changes produced by repetitive apomorphine treatments in rats

Repeated psychostimulants induce electroencephalographic (EEG) changes, which reflect adaptation of the neural substrate related to dopaminergic pathways. To study the role of dopamine receptors in EEG changes, we examined the effect of apomorphine, the dopamine D1 receptor antagonist, SCH-23390, and the D2 receptor antagonist, haloperidol, on EEG in rats. For single and repeated apomorphine treatment groups, the rats received saline or apomorphine for 4 days followed by a 3-day withdrawal period and then apomorphine (2.5 mg/kg, i.p.) challenge after pretreatment with saline, SCH-23390, or haloperidol on the day of the experiment. EEGs from the frontal and parietal cortices were recorded. On the frontal cortex, apomorphine decreased the power of all the frequency bands in the single treatment group, and increased the theta (4.5~8 Hz) and alpha (8~13 Hz) powers in the repeated treatment group. Changes in both groups were reversed to the control values by SCH-23390. On the parietal cortex, single apomorphine treatment decreased the power of some frequency bands, which were reversed by haloperidol but not by SCH-23390. Repeated apomorphine treatment did not produce significant changes in the power profile. These results show that adaptation of dopamine pathways by repeated apomorphine treatment could be identified with EEG changes such as increases in theta and alpha power of the frontal cortex, and this adaptation may occur through changes in the D1 receptor and/or the D2 receptor.

The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques

Anhedonia, the reduced propensity to experience pleasure, is a promising endophenotype and vulnerability factor for several psychiatric disorders, including depression and schizophrenia. In the present study, we used resting electroencephalography, functional magnetic resonance imaging, and volumetric analyses to probe putative associations between anhedonia and individual differences in key nodes of the brain's reward system in a non-clinical sample. We found that anhedonia, but not other symptoms of depression or anxiety, was correlated with reduced nucleus accumbens (NAcc) responses to rewards (gains in a monetary incentive delay task), reduced NAcc volume, and increased resting delta current density (i.e., decreased resting activity) in the rostral anterior cingulate cortex (rACC), an area previously implicated in positive subjective experience. In addition, NAcc reward responses were inversely associated with rACC resting delta activity, supporting the hypothesis that delta might be lawfully related to activity within the brain's reward circuit. Taken together, these results help elucidate the neural basis of anhedonia and strengthen the argument for anhedonia as an endophenotype for depression.

The involvement of dopamine in the modulation of sleep and waking

Dopamine (DA)-containing neurons involved in the regulation of sleep and waking (W) arise in the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNc). The VTA and SNc cells have efferent and afferent connections with the dorsal raphe nucleus (DRN), the pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT), the locus coeruleus (LC), the lateral and posterior hypothalamus (LH), the basal forebrain (BFB), and the thalamus. Molecular cloning techniques have enabled the characterization of two distinct groups of DA receptors, D(1)-like and D(2)-like receptors. The D(1) subfamily includes the D(1) and D(5) receptors, whereas the D(2) subfamily comprises the D(2), D(3), and D(4) receptors. Systemic administration of a selective D(1) receptor agonist induces behavioral arousal, together with an increase of W and a reduction of slow wave sleep (SWS) and REM sleep (REMS). Systemic injection of a DA D(2) receptor agonist induces biphasic effects, such that low doses reduce W and increase SWS and REMS (predominant activation of the D(2) autoreceptor), whereas large doses induce the opposite effect (predominant facilitation of the D(2) postsynaptic receptor). Compounds with DA D(1) or D(2) receptor blocking properties augment non-REMS and reduce W. Preliminary findings tend to indicate that the administration of a DA D(3)-preferring agonist induces somnolence and sleep in laboratory animals and man. DA neurons in the VTA and the SNc do not change their mean firing rate across the sleep-wake cycle. It has been proposed that DA cells in the midbrain show a change in temporal pattern rather than firing rate during the sleep-wake cycle. The available evidence tends to indicate that during W there occurs an increase of burst firing activity of DA neurons, and an enhanced release of DA in the VTA, the nucleus accumbens (NAc), and a number of forebrain structures. A series of structures relevant for the regulation of the behavioral state, including the DRN, LDT/PPT, LC, and LH, could be partly responsible for the changes in the temporal pattern of activity of DA neurons.

Motivation, emotion, and their inhibitory control mirrored in brain oscillations

Recent studies suggest brain oscillations as a mechanism for cerebral integration. Such integration can exist across a number of functional domains, with different frequency rhythms associated with each domain. Here, evidence is summarized which shows that delta oscillations depend on activity of motivational systems and participate in salience detection. Theta oscillations are involved in memory and emotional regulation. Alpha oscillations participate in inhibitory processes which contribute to a variety of cognitive operations such as attention and memory. The importance of inhibitory functions associated with alpha oscillations increases during the course of evolution. In ontogenesis, these functions develop later and may be more sensitive to a variety of detrimental environmental influences. In a number of developmental stages and pathological conditions, a deficient alpha and/or increased slow-wave activity are associated with cognitive deficits and a lack of inhibitory control. It is shown that slow-wave and alpha oscillations are reciprocally related to each other. This reciprocal relationship may reflect an inhibitory control over motivational and emotional drives which is implemented by the prefrontal cortex.

Striatal dopaminergic stimulation produces c-Fos expression in the PPT and an increase in wakefulness

Striatal activation can modify activity in cortical areas related to specific striatal functions possibly through a process of disinhibition within the basal ganglia. Anatomical studies have shown substantial GABAergic innervation from these nuclei to the pedunculopontine tegmental nucleus (PPT). Thus, dopaminergic stimulation of the striatum could produce PPT disinhibition and result in non-specific cortical activation. To test this hypothesis, d-amphetamine was infused both into the striatum of freely moving rats for motor and electrocorticographic recordings, and into the striatum of animals under deep anesthesia for c-Fos immunohistochemistry. The results show that intrastriatal amphetamine increases wakefulness independent of motor activity, and it increases c-Fos expression in the PPT and adjacent areas. They also suggest that the striatum participates in non-specific cortical activation probably as a result of its relationship with the PPT.

EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease

In rats bearing a unilateral 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle, a single administration of a dopamine receptor agonist (priming) sensitizes the behavioral motor responses to a dopaminergic agonist, administered 3 days after priming. In this study, changes in the electroencephalogram (EEG) frequency spectra were evaluated during priming in unilaterally 6-OHDA-lesioned rats, implanted bilaterally with electrodes both in the somatosensory cortex and striatum. Two weeks after 6-OHDA lesion, rats were primed with apomorphine (0.2 mg/kg) and received a challenge with the D(1) agonist SKF 38393 (3 mg/kg) 3 days later. 6-OHDA lesion modified the EEG pattern mainly in the beta(1) frequency band, in both cortex and striatum. Apomorphine priming produced a power decrease in the beta(1) frequency band, more pronounced in the cortex than in the striatum, as compared to saline-treated rats. Antagonism of NMDA receptor with MK-801, a treatment known to block the development of priming, increased apomorphine inhibitory effect mainly in the striatum, producing the same degree of inhibition in the two structures. Administration of SKF 38393, 3 days after priming, caused a power decrease in beta(1) frequency band of the cortex and striatum, which was more pronounced in apomorphine-primed as compared to drug-naive rats. The inhibitory effect of SKF 38393 was enhanced in rats primed with MK-801 plus apomorphine, particularly in the striatum. The results of this study suggest that long-term changes in the electrical activity of cortex and striatum after priming, might contribute to the development of the behavioral sensitization observed after priming. Development of priming might be related to the degree and cortical/striatal ratio of EEG power inhibition produced by dopamine agonists.

Amphetamine acts within the medial basal forebrain to initiate and maintain alert waking

Amphetamine-like stimulants exert well-known arousal-enhancing actions. Surprisingly, little is known concerning the neuroanatomical substrates through which these drugs enhance arousal. Previous work implicates a number of basal forebrain structures in the regulation of behavioral state. The current studies examined the effects of amphetamine infusions made directly within basal forebrain sites on behavioral, electroencephalographic, and electromyographic indices of arousal in anesthetized and unanesthetized rat. In the anesthetized rat, amphetamine elicited prolonged epochs of bilateral electroencephalographic activation when infused unilaterally (3.75 microg/150 nl) into an extended region of the medial basal forebrain, demarcated anteriorally by the anterior portion of the medial septal area (which includes posterior accumbens shell) and posteriorally by the posterior aspect of the preoptic area of the hypothalamus. In the unanesthetized (undisturbed, resting) rat, amphetamine infusions into this region elicited prolonged epochs of alert waking, which at the lowest dose (3.75 microg), qualitatively resembled normal waking. Infusions placed lateral (including within the substantia innominata), anterior (including within the core subregion of the nucleus accumbens), posterior, or dorsal to these structures, as well as directly within the lateral ventricles did not alter electroencephalographic or behavioral measures. These results indicate that a region of the medial basal forebrain, extending from the anterior medial septum/accumbens shell to the posterior preoptic area, is a site within which amphetamine-like stimulants act to enhance behavioral and electroencephalographic measures of arousal.

Beta-adrenoceptor blockade and open-field behavior in male golden hamsters

Open-field behavior was compared between untreated, saline-treated, and butoxamine (a beta-2-adrenoceptor antagonist) treated (15 and 5 mg/kg body weight) male golden hamsters (Mesocricetus auratus). Butoxamine-treated males spent significantly more time self-grooming than saline-treated and untreated males. Especially, untreated males and very similar saline control males showed a clear time sequential structure of behavior with two axes: a grooming-grooming sequence and a highly organized flankmark followed by scrape axis. The degree of this organization was markedly decreased in the butoxamine-treated males, showing an increase in organization of the transition between grooming acts. In general, these males displayed a more stereotypic pattern of behavior than the other. To reveal a systematic relation between the flankmark-scrape response and the exposition to butoxamine and to keep the numbers of experimental animals low, mixed samples were created through consecutive summing of the individual transition matrices of six males treated with 5 mg/kg b.wt. butoxamine to the 15 mg/kg b.wt. sample. By analyzing all samples separately, a positive linear relation between the number of low dosed males in the samples and the degree of organization of the flankmark-scrape sequence was found. The results suggest that the analysis of the transitional structure of behavior during short-term challenges can considerably contribute to an estimation of the coping style and seems to be a more sensitive method than comparing frequencies of behavioral indicators of stress.

Selective agonists of metabotropic glutamate receptors elicit significant EEG effects when infused in the nucleus accumbens of rats

The effect of intra-accumbens infusion of selective group I ((S)-3,5-dihydroxyphenylglycine, DHPG), group II ((2S,3S,4S)-CCG/(2S,1'S,2'S)-2-(carboxycyclopropyl)glycine, L-CCG-I) and group III ((L-(+)-2-amino-4-phosphonobutyric acid, L-AP4) metabotropic glutamate (mGlu) receptor agonists was studied in male Wistar rats. A computerised electroencephalographic (EEG) power spectral analysis was performed. While DHPG (400 nmoles) induced EEG and behavioural limbic seizures, L-CCG-I (400 nmoles) and L-AP4 (800 nmoles) induced a 'depressant' EEG with an increase in relative power in the slow-frequency bands and a decrease in relative power in the high-frequency bands) and behavioural effects. These results show for the first time that the stimulation of groups I, II and III mGlu receptors located in the nucleus accumbens significantly influences the EEG tracing in rats.

Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats

Both N6-cyclopentyladenosine (CPA, adenosine A1 receptor agonist) and 2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamido-adenosi ne (CGS 21680, adenosine A2 receptor agonist) inhibited the electroencephalographic (EEG) effects induced by the noncompetitive NMDA receptor antagonist (+)-5-methyl-10,11-dihydro-5H-dibenzo-(a,d)cyclohepten-5,10-imine maleate (MK-801) in rats. While the inhibitory effects of CPA were evident at doses (0.1 and 0.5 mg/kg i.p.) devoid of intrinsic behavioral effects, CGS 21680 was effective only when administered at depressant doses (2 mg/kg i.p.). Since the effects induced by NMDA receptor antagonists may be regarded as a model of psychosis, these results suggest a possible role of adenosine receptor agonists as antipsychotics.

Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety

1. The appearance of frontal midline theta activity (Fm theta), the distinct EEG theta rhythm in the frontal midline area during performance of a mental task, indicates relief from anxiety in humans. 2. The authors examined the effects of bromocriptine and sulpiride on anxiety and arousal in 24 male university students with (Fm theta group, n = 12) and without (non-Fm theta group, n = 12) Fm theta. Subjects were given placebo, 2.5 mg bromocriptine and 100 mg sulpiride in a double-blind crossover design. 3. Blood samples were obtained, STAI scores were determined, and EEGs were recorded before and during the performance of an arithmetic addition task. The test was repeated twice: before and 1 hr after drug administration. 4. Bromocriptine reduced the HVA concentration in both groups; sulpiride caused an increase in both groups. In the Fm theta group, bromocriptine did not alter the appearance time of Fm theta, the state anxiety score or the task performance; sulpiride increased the Fm theta amount and reduced the state anxiety but did not affect the task performance. In the non-Fm theta group, bromocriptine increased the Fm theta duration and reduced the state anxiety score but did not influence the task performance, while sulpiride reduced Fm theta and increased the state anxiety but had no effect on the task performance. 5. These results suggest that the sensitivity of presynaptic D2 receptors is higher in high-anxiety subjects compared with low-anxiety subjects, and that anxiolytic effects in high-anxiety humans and those in low-anxiety humans may be caused by decreased and increased DA activity, respectively. In addition, the stimulation of DA function may cause anxiogenic effects in high-anxiety individuals.

Amphetamine and haloperidol modulatory effects on Purkinje cell activity and on EEG power spectra in the acute rat model of epilepsy

The modulation of cerebellar Purkinje cell activity and EEG from parietal cortex was studied in the rat model of epilepsy induced by penicillin under acute haloperidol and amphetamine treatment. The discharge pattern of Purkinje cells showed tendency towards inhibition and EEG power spectra increased after parenteral administration of penicillin (1000000 IU/kg, i.p.). Acute haloperidol treatment (1 mg/kg, i.p.), performed after the development of penicillin induced epileptic episodes, elicited a prominent excitation of Purkinje cell discharges associated with parallel increase in mean EEG power spectra. However, acute DL-amphetamine treatment induced marked suppression of Purkinje cell discharges as well as outstanding decrease of the mean EEG power spectra. These results indicate that cerebellar Purkinje cells may be important in the control of seizure activity and that noradrenergic influences are relevant.

Activation of dopamine D1 receptors or alpha 1 adrenoceptors is not involved in the EEG effect of nicotine in rats

Based on previous own EEG-studies and behavioural studies of other authors, it has been claimed recently that D1 receptors are involved in addictive properties of drugs. It seemed, therefore, of interest to study whether nicotine produces D1-characteristic EEG alterations in rats. EEG was recorded in non-anesthetized, freely moving rats, transmitted telemetrically and underwent power spectral analysis. Nicotine (0.1, 0.2, 0.4 mg/kg s.c.) produced a desynchronization in the EEG and a decrease of power in all of the frequency bands (delta, theta, alpha 1, alpha 2, beta 1) except in beta 2. With regard to behaviour, an increase of locomotor activity and some discontinuous sniffing was manifest. The effect of nicotine (0.2 mg/kg) was not antagonized by blockade of dopamine D1 receptors by SCH 23390 (0.1 mg/kg s.c., 30 min before nicotine), although this drug by itself increased the power in most of the frequency bands. Prazosine (0.2 mg/kg i.p.), a selective antagonist at alpha 1 adrenoceptors, by itself increased the power in all of the frequency bands, but also failed to antagonize the effects of nicotine (0.2 mg/kg). In contrast, the blocker of nicotinic cholinoceptors mecamylamine (1 mg/kg i.p.) was effective in antagonizing the action of nicotine on the EEG. The results suggest that in nicotine-mediated desynchronization and decrease of power in the EEG, the activation of dopamine D1 or alpha 1 adrenoceptors is not involved.

Studies on electroencephalogram (EEG) in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors

The effects of cocaine and d-amphetamine, two psychomotor stimulant drugs with pronounced addictive properties, on the electroencephalogram (EEG) of rats were studied by telemetric recordings from the skull in non-anesthetized, freely moving rats. The electrocorticogram (ECoG) was recorded. Both cocaine (10 mg/kg IP) and d-amphetamine (0.4 mg/kg IP) produced a desynchronization, characterized by a general lowering in power in all of the frequency bands. These effects of both drugs were mimicked by the selective agonist at D1 receptors SK&F 38393 (3 mg/kg SC) and were reversed by the antagonist at D1 receptors SCH 23390 (0.2 mg/kg IP) but not influenced by haloperidol (0.1 mg/kg IP) in a dose which is likely to block D2 rather than D1 receptors. These doses of cocaine or d-amphetamine did not produce stereotyped behaviour and slight, if any, increases in locomotor activity only. Large doses of cocaine (30 mg/kg IP) or d-amphetamine (4 mg/kg IP) produced stereotyped behaviour and alterations in EEG which are, based on previous own studies, characteristic for additional stimulation of D2 receptors. This was manifest in a selective increase in power of the alpha-1 band. A similar effect was also produced by the agonist both at D1 and D2 receptors, apomorphine (0.5 mg/kg SC). These results suggest that moderate, but probably rewarding doses of cocaine or d-amphetamine mainly activate D1 dopamine receptors. This activation might be relevant for the rewarding properties of these drugs.